Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Phase I/II Study Of Kevetrin With Cytarabine In Patients With Acute Myelogenous Leukemia (AML)

Next Previous
Trial Profile

A Multi-Center, Open-Label, Phase I/II Study Of Kevetrin With Cytarabine In Patients With Acute Myelogenous Leukemia (AML)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Thioureidobutyronitrile (Primary) ; Cytarabine; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 21 Apr 2015 Planned initiation date changed to 1 May 2015. The new protocol will be submitted in May by the principal investigator at the University of Bologna to the institutional committee, according to a Cellceutix Corporation media release.
    • 21 Apr 2015 Planned number of patients changed to 100. Over 100 patients are expected to be enrolled in the trial, according to a Cellceutix Corporation media release.
    • 21 Apr 2015 The original protocol has been revised and expanded from what was originally planned to be a Phase 1b study into a Phase 2 trial evaluating Kevetrin as a single agent or in combination with cytarabine in patients with Acute Myelogenous Leukemia (AML). The new protocol will be submitted in May by the principal investigator at the University of Bologna to the institutional committee, according to a Cellceutix Corporation media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top